Page 4 - மைய உரிமம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Health Ministry, validity of regular medical Devices license extended for 6 months
patrika.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from patrika.com Daily Mail and Mail on Sunday newspapers.
Oriole Resources PLC identifies gold targets in central Cameroon
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Thận trọng, chặt chẽ, kỹ lưỡng trong công tác chuẩn bị nhân sự BCH Trung ương khóa XIII
baomoi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baomoi.com Daily Mail and Mail on Sunday newspapers.
Text Size:
A+
The year 2021 in India began with a flurry of events around the Covid-19 vaccine. The Indian government conducted dry runs for the vaccines, and two vaccines Covishield (Oxford University-AstraZeneca) and Covaxin (Bharat Biotech) were granted
accelerated regulatory approval by the Central Drugs Standard Control Organisation (CDSCO). The process of granting these vaccines regulatory approval has been a subject of intense scrutiny. The grant of these approvals and the scrutiny involved in the process has been marred with several concerns as these vaccines are yet to complete Phase III clinical trials.
In this blog, we examine the regulatory underpinnings of the approvals granted to Covishield and Covaxin, and attempt to shed light on the existing legal framework dealing with the approval of drugs for emergency use.
Bharat Biotech Announced Successful Completion Of Volunteer Enrolment For Phase3 Clinical Trials Of Covaxin - कोवैक्सीन : तीसरे चरण के ट्रायल की अड़चनें खत्म, पूरा हो गया ये बड़ा काम
amarujala.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from amarujala.com Daily Mail and Mail on Sunday newspapers.